Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Max Liebregts

Showing results (11-20 of 39) with videos related to

Pageof 4
Sort By:
JACC. Heart Failure|October 12, 2015
A Systematic Review and Meta-Analysis of Long-Term Outcomes After Septal Reduction Therapy in Patients With Hypertrophic CardiomyopathyMax Liebregts, Pieter A Vriesendorp, Bakhtawar K Mahmoodi, et al.
International Journal of Cardiology|January 25, 2016
FOLFOX chemotherapy as a cause of ventricular septal rupture after alcohol septal ablation for obstructive hypertrophic cardiomyopathy?Max Liebregts, Guus M Bol, Jan-Willem Groen, et al.
JACC. Cardiovascular Interventions|October 20, 2014
Periprocedural complications and long-term outcome after alcohol septal ablation versus surgical myectomy in hypertrophic obstructive cardiomyopathy: a single-center experienceRobbert C Steggerda, Kevin Damman, Jippe C Balt, et al.
International Journal of Cardiology|February 21, 2016
Low procedure-related mortality achieved with alcohol septal ablation in European patientsJosef Veselka, Morten Kvistholm Jensen, Max Liebregts, et al.
Circulation. Arrhythmia and Electrophysiology|April 30, 2015
Validation of the 2014 European Society of Cardiology guidelines risk prediction model for the primary prevention of sudden cardiac death in hypertrophic cardiomyopathyPieter A Vriesendorp, Arend F L Schinkel, Max Liebregts, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|March 7, 2016
Effect of alcohol dosage on long-term outcomes after alcohol septal ablation in patients with hypertrophic cardiomyopathyMax Liebregts, Pieter A Vriesendorp, Robbert C Steggerda, et al.
JACC. Cardiovascular Interventions|June 25, 2021
Sex-Related Differences in Outcomes of Alcohol Septal Ablation for Hypertrophic Obstructive CardiomyopathyJosef Veselka, Lothar Faber, Max Liebregts, et al.
JACC. Heart Failure|December 3, 2014
Long-term outcomes after medical and invasive treatment in patients with hypertrophic cardiomyopathyPieter A Vriesendorp, Max Liebregts, Robbert C Steggerda, et al.
Heart Rhythm|May 26, 2026
Dosing of Single-Shot Pulsed Field Ablation Systems: a Systematic Review of Efficacy and Safety BalanceIsabelle N Bax, Roos E Bolhuis, Marisa van der Graaf, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|October 11, 2017
Validation of the HCM Risk-SCD model in patients with hypertrophic cardiomyopathy following alcohol septal ablationMax Liebregts, Lothar Faber, Morten K Jensen, et al.
Pageof 4

Showing results (11-20 of 39) with videos related to

Sort By:
Pageof 4
JACC. Heart Failure|October 12, 2015
A Systematic Review and Meta-Analysis of Long-Term Outcomes After Septal Reduction Therapy in Patients With Hypertrophic CardiomyopathyMax Liebregts, Pieter A Vriesendorp, Bakhtawar K Mahmoodi, et al.
International Journal of Cardiology|January 25, 2016
FOLFOX chemotherapy as a cause of ventricular septal rupture after alcohol septal ablation for obstructive hypertrophic cardiomyopathy?Max Liebregts, Guus M Bol, Jan-Willem Groen, et al.
JACC. Cardiovascular Interventions|October 20, 2014
Periprocedural complications and long-term outcome after alcohol septal ablation versus surgical myectomy in hypertrophic obstructive cardiomyopathy: a single-center experienceRobbert C Steggerda, Kevin Damman, Jippe C Balt, et al.
International Journal of Cardiology|February 21, 2016
Low procedure-related mortality achieved with alcohol septal ablation in European patientsJosef Veselka, Morten Kvistholm Jensen, Max Liebregts, et al.
Circulation. Arrhythmia and Electrophysiology|April 30, 2015
Validation of the 2014 European Society of Cardiology guidelines risk prediction model for the primary prevention of sudden cardiac death in hypertrophic cardiomyopathyPieter A Vriesendorp, Arend F L Schinkel, Max Liebregts, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|March 7, 2016
Effect of alcohol dosage on long-term outcomes after alcohol septal ablation in patients with hypertrophic cardiomyopathyMax Liebregts, Pieter A Vriesendorp, Robbert C Steggerda, et al.
JACC. Cardiovascular Interventions|June 25, 2021
Sex-Related Differences in Outcomes of Alcohol Septal Ablation for Hypertrophic Obstructive CardiomyopathyJosef Veselka, Lothar Faber, Max Liebregts, et al.
JACC. Heart Failure|December 3, 2014
Long-term outcomes after medical and invasive treatment in patients with hypertrophic cardiomyopathyPieter A Vriesendorp, Max Liebregts, Robbert C Steggerda, et al.
Heart Rhythm|May 26, 2026
Dosing of Single-Shot Pulsed Field Ablation Systems: a Systematic Review of Efficacy and Safety BalanceIsabelle N Bax, Roos E Bolhuis, Marisa van der Graaf, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|October 11, 2017
Validation of the HCM Risk-SCD model in patients with hypertrophic cardiomyopathy following alcohol septal ablationMax Liebregts, Lothar Faber, Morten K Jensen, et al.
Pageof 4